Trial Profile
Phase 2 study of talabostat and docetaxel [Taxotere] in advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2007
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Talabostat (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jan 2007 Status change
- 11 Sep 2005 New trial record.